期刊文献+

HPLC法测定卡培他滨的含量及有关物质 被引量:4

Determination of content and related substances of Capecitabine by HPLC
暂未订购
导出
摘要 目的建立高效液相色谱法测定卡培他滨含量及有关物质的方法。方法采用C18柱,以B(甲醇:乙腈:0.1%醋酸=7:0.2:12.8)-C(甲辟:乙腈:0.1%醋酸=16:1:3)为流动相,梯度洗脱,流速为1.OmL·min-1,进样量为10μL,检测波长为250nm,柱温为40℃,自动进样室为5℃。结果在浓度为0.0997-0.997mg·mL-1范围内线性关系良好(r=0.9999,n=6),检测限为0.020μg·mL^-1。该方法能够分离卡培他滨及其有关物质。结论本方法灵敏、准确、专属性及重复性好。可用于卡培他滨的含量测定及有关物质限量检查。 OBJECTIVE To establish a HPLC method for the determination of the content and related sub- stances of Capecitabine. METHODS C18 column was used, the mobile phase was B( methanol : acetonitrile: 0.1% acetic acid = 7: 0.2:12.8)-C(methanol: acetonitrile: 0.1% acetic acid = 16:1 : 3) by gradient elution, the flow rate was 1.0mL-min-1. The injection volume was 10μL, detection wavelength was set at 250nm, the column tempera- ture was 40℃ and the automatic sampling temperature was 5℃. RESUTLS The calibration curve was linear in the range of 0. 0997-0. 997mg.mL- 1, r= 0. 9999(n = 6) ; the limit of detection was 0. 020μg.mL- 1. The related substances were completely separated from Capecitabine by using this method. CONCLUSION With good sensi- tivity, accuracy, selectivity and reproducibility, the method is applicable for the determination of Capecitabine and its related substances.
出处 《海峡药学》 2013年第1期48-51,共4页 Strait Pharmaceutical Journal
关键词 卡培他滨 含量测定 有关物质 HPLC法 Capecitabine Content Related substances HPLC
  • 相关文献

参考文献5

二级参考文献30

  • 1余建鑫,张万年,姚建忠,宋云龙,盛春泉.抗肿瘤药物卡培他滨的合成工艺改进[J].中国药物化学杂志,2005,15(3):173-175. 被引量:21
  • 2龙绪江,陈国华,朱航昌,李强,吴斐华.米格列奈类似物的合成及其降血糖作用[J].中国药科大学学报,2005,36(5):398-401. 被引量:4
  • 3《卫生部颁药品标准》二部第四册.
  • 4《USP30》.
  • 5《EP6.0》.
  • 6Brinkman HR, Kalaritis P, Morrissey JF. Process for producing N4-acyl-5'-deoxy-5-Fluoro-cytidine derivatives [ P ]. US : 5476932A, 1995- 12-19.
  • 7Shimma N,Umeda I. The design and synthesis of a new tumor-selective tluoropyrimidine carbamate, capeeitabine [ J ]. Bioorg Med Chem, 2000,8(7) :1697-1706.
  • 8Arasaki M, Ishitsuka H, Kuruma I, et al. N4-( substituted-oxycarbonyl ) -5' -deoxy-5-fluorocytidine compounds, compositions and methods of using same[ P]. US:5472949A. 1995-12-05.
  • 9SHANDONG Xinhua Pharmaceutical Factory.Process toprepare brufen by rearranging molecular under catalysis:China1082022.A[P].1994-02-16.
  • 10CHANGSHA University of Science&Technology.Methodfor preparing ibuprofen:China 101456808.A[P].2009-06-17.

共引文献33

同被引文献37

  • 1陈越磊,岑均达.卡培他滨类似物的合成及体内抗肿瘤活性[J].中国药物化学杂志,2004,14(5):277-279. 被引量:10
  • 2叶敏,付强,朱珠.高效液相色谱法测定人血浆中卡培他滨浓度[J].中国医院药学杂志,2004,24(11):678-680. 被引量:4
  • 3霍秀敏.稳定性试验与药品的有效期[J].药品评价,2007,4(1):56-58. 被引量:29
  • 4国家食品药品监督管理局.化学药物质量标准建立的规范化过程技术指导原则[Z].2005.
  • 5USP34-NF29 (2010).The United States Pharmacopeial Convention[S].
  • 6国家食品药品监督管理局.化学药物质量控制分析方法验证技术指导原则[Z].2005.
  • 7国家食品药品监督管理局.化学药物稳定性研究技术指导原则[Z].2005.
  • 8Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine [J]. Bioorg Med Chem,2000,8(7) :1697 -1706.
  • 9Miles D, Zielinski C, Martin M, et al. Combining capeeitabin: and bevacizumab in metastatic breast cancer: A comprehensive review [J]. European Journal of Cancer,2012,48(4) :482 -491.
  • 10季俊虬,高美华,李孝常,等.一种卡培他滨中间体的简便精制方法:中国,CN201310674404.4[P].2013-12-13.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部